Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Alzheimer's Disease
Interventions: Dronabinol (Marinol®), Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 95 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Baltimore, Maryland • Belmont, Massachusetts + 2 more

Conditions: Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: AL3818, Nivolumab Injection; Drug
Lead sponsor: Sarcoma Oncology Research Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Healthy
Interventions: Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, BMS-986094, Ribavirin, Placebo for BMS-986094; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Xerostomia, Sjogren's Syndrome
Interventions: NGX267; Drug
Lead sponsor: TorreyPines Therapeutics; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Duncansville, Pennsylvania • Philadelphia, Pennsylvania • Austin, Texas

Conditions: Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions: (Z)-endoxifen, goserelin; Drug
Lead sponsor: Atossa Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Post Traumatic Stress Disorder, Depression - Major Depressive Disorder
Interventions: Psilocybin + MBCT therapy, Active Comparator: Psilocybin with Support Only; Combination Product
Lead sponsor: Anthony P King; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Immune Surveillance
Interventions: Agaricus blazei, Reishi, Turkey Tail, Placebo; Dietary Supplement · Other
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Major Depressive Disorder
Interventions: venlafaxine (Effexor), placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pharmacokinetics
Interventions: Kava Dietary Supplement, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Metastatic Breast Cancer, Breast Carcinoma
Interventions: LEE-011, Fulvestrant, Placebo; Drug
Lead sponsor: Melissa K Accordino; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Interstitial Cystitis, Painful Bladder Syndrome
Interventions: PD 0299685 at 15mg BID, PD 0299685 at 30mg BID, placebo for PD 0299685; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 23
States / cities: Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 20 more

Conditions: Healthy Volunteers
Interventions: 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Joint Health
Interventions: MyCondro 300mg, MyCondro 600mg; Dietary Supplement
Lead sponsor: Lesaffre International; Industry
Eligibility: 45 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoporosis (Senile)
Interventions: doxercalciferol capsules, Hectorol®, Matched Placebo (Capsules); Drug
Lead sponsor: Creighton University; Other
Eligibility: 60 Years to 78 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 1994
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Healthy
Interventions: Fluoxetine Capsules 40 mg, Prozac Pulvules 40 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Neimann-Pick Disease
Interventions: Vorinostat; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria, Dietary Hyperoxaluria
Interventions: ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Los Angeles, California • Daytona Beach, Florida • Jacksonville, Florida + 13 more

Conditions: Healthy
Interventions: ALXN2050, Cyclosporine, Tacrolimus, MMF; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: celecoxib; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Lupus Erythematosus, Systemic
Interventions: Memantine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Cleveland, Ohio • Nashville, Tennessee • Houston, Texas

Conditions: Atrial Fibrillation
Interventions: Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Beverly Hills, California • Newport Beach, California • San Francisco, California + 12 more

Conditions: Hodgkin Lymphoma
Interventions: PLX3397; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Rochester, Minnesota + 3 more

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Rilpivirine, Placebo; Drug
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Newark, New Jersey • The Bronx, New York

Search by objective public record fields.

Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Mindfulness-based Psilocybin Therapy for PTSD

Clinical Trial: Rapid Immune Modulating Effects

Electroencephalography (EEG) Biomarkers of Response in Depression

Biomarker Changes and Anxiolytic Effects-Phase 2

Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health

To Study the Efficacy and Safety of Doxercalciferol on Spinal and Femoral Density in Postmenopausal Osteopenic Women in a Long Term 2 Year Study

Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg

Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis